Shire has won US approval for a long-acting attention-deficit drug aimed at adolescents and adults. This boosts its stock of medicines for the cognitive condition that affects millions of children and is being diagnosed more in older people. The US Food and Drug Administration’s (FDA’s) approval for Mydayis follows good results for Shire’s new hereditary angioedema drug and helps offset the setback of early generic competition to a Shire drug for ulcerative colitis. The new drug Mydayis, previously known as SHP465, contains the same active ingredient as Shire’s widely used attention deficit hyperactivity disorder (ADHD) treatment Adderall XR, but is formulated to last up to 16 hours. Adderall XR, which is also available in generic forms, manages symptoms for up to 12 hours. "It’s obviously not a new molecule but it does extend delivery," said Gregory Mattingly, who has been a study investigator in multiple Shire ADHD drug trials. Shire, whose ADHD drugs Adderall XR and Vyvanse gener...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.